We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

158 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 43 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $765K

35% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 43

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

13% more capital invested

Capital invested by funds: $841M → $953M (+$111M)

0.32% more ownership

Funds ownership: 68.76% → 69.08% (+0.32%)

0% more funds holding

Funds holding: 158 → 158 (0)

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

Holders
158
Holders Change
–
Holders Change %
0%
% of All Funds
2.48%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
26
Increased
58
Reduced
43
Closed
26
Calls
$1.04M
Puts
$765K
Net Calls
+$272K
Net Calls Change
+$22K

Top Buyers

1
KA
Kinnevik AB
Sweden
+$19.3M
2
YRHAM
Yong Rong (HK) Asset Management
Hong Kong
+$8.22M
3
AIM
ARK Investment Management
Florida
+$8.13M
4
BlackRock
BlackRock
New York
+$6.91M
5
LIM
Lingotto Investment Management
United Kingdom
+$5.42M

Top Sellers

1
LCM
Laurion Capital Management
New York
-$11.5M
2
Norges Bank
Norges Bank
Norway
-$9.51M
3
State Street
State Street
Massachusetts
-$4.72M
4
HMC
Harvard Management Company
Massachusetts
-$4.39M
5
Millennium Management
Millennium Management
New York
-$4.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
Baillie Gifford & Co
1
Baillie Gifford & Co
United Kingdom
$187M -$265K -37,900 -0.2%
BlackRock
2
BlackRock
New York
$86.8M +$6.91M +987,570 +9%
Vanguard Group
3
Vanguard Group
Pennsylvania
$84.1M +$2.28M +326,248 +3%
KA
4
Kinnevik AB
Sweden
$77.7M +$19.3M +2,752,607 +36%
MCMU
5
MIC Capital Management (UK)
United Kingdom
$63.1M – – –
DCI
6
Data Collective IV
California
$44.4M – – –
State Street
7
State Street
Massachusetts
$42.6M -$4.72M -674,583 -11%
AIM
8
ARK Investment Management
Florida
$35.4M +$8.13M +1,161,655 +32%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$34.1M -$1.37M -195,864 -4%
LCM
10
Laurion Capital Management
New York
$23.7M -$11.5M -1,647,556 -34%
Norges Bank
11
Norges Bank
Norway
$21.4M -$9.51M -1,358,868 -32%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$21M +$459K +65,659 +2%
PIM
13
Platinum Investment Management
Australia
$20.3M -$415K -59,303 -2%
MMX
14
MV Management XI
California
$14.7M – – –
CS
15
Credit Suisse
Switzerland
$12.7M +$822K +117,518 +7%
DFO
16
Duquesne Family Office
New York
$10.4M – – –
Northern Trust
17
Northern Trust
Illinois
$9.35M +$673K +96,210 +8%
YRHAM
18
Yong Rong (HK) Asset Management
Hong Kong
$8.77M +$8.22M +1,174,200 New
N
19
Nuveen
North Carolina
$8.41M +$700K +100,060 +10%
AI
20
ArchPoint Investors
Florida
$8.33M – – –
CFM
21
Comprehensive Financial Management
California
$8.29M – – –
Charles Schwab
22
Charles Schwab
California
$7.48M +$118K +16,838 +2%
CM
23
Cercano Management
Washington
$7.31M – – –
HMC
24
Harvard Management Company
Massachusetts
$6.59M -$4.39M -627,125 -42%
Sumitomo Mitsui Trust Group
25
Sumitomo Mitsui Trust Group
Japan
$6.26M +$2.35M +335,423 +67%
1
2 3 4 5

RXRX Hedge Fund Activity: Q2 2023 in Review

158 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2023, worth a combined $953M — up 13% from $841M a quarter earlier.

Fund positioning in RXRX was balanced in Q2 2023: 26 funds opened new positions, 26 closed out, 58 added to existing stakes and 43 trimmed.

The largest buyer was Kinnevik AB, adding an estimated $19.3M. The largest seller was Laurion Capital Management, cutting an estimated $11.5M.

  • 158 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $953M of Recursion Pharmaceuticals stock for Q2 2023, up 13% quarter-over-quarter.
  • 26 funds opened new Recursion Pharmaceuticals positions in Q2 2023 and 26 closed out, a net change of 0 holders.
  • The largest Recursion Pharmaceuticals buyer in Q2 2023 was Kinnevik AB, an estimated $19.3M added.
  • The largest Recursion Pharmaceuticals seller in Q2 2023 was Laurion Capital Management, an estimated $11.5M sold.

Based on aggregated 13F filings for Q2 2023.